Publications
- Osimertinib - a new treatment option for patients with EGFR mutation T790M2017 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Influence of expression of selected genes encoding proteins and microRNA on the risk of stage 1 pulmonary adenocarcinoma relapse2017 | Faculty of Medicine in Pilsen
- Crizotinib - Still "gold standard" for patients with pulmonary adenocarcinoma with ALK translocation?2017 | Faculty of Medicine in Pilsen
- Successful Therapy of Czech Patients with ROS1 Translocation by Crizotinib2016 | Faculty of Medicine in Pilsen
- Nintedanib - interesting alternative forsecond line pulmonaty adenocarcinoma patients2016 | Faculty of Medicine in Pilsen
- LUX-LUNG 7 - new look at the first line treatment for patients with frequent EGFR mutations?2016 | Faculty of Medicine in Pilsen
- Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer2023 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové, Central Library of Charles University, Third Faculty of Medicine
- Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC2023 | Faculty of Medicine in Pilsen, Faculty of Science, Central Library of Charles University
- Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer2023 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Preoperative Plasma miRNA Levels Predict Prognosis in Early-stage Malignant Melanoma2023 | Faculty of Medicine in Pilsen
Loading network view...